Core Insights - Cytek Biosciences, Inc. has achieved a significant milestone in its Asia-Pacific expansion with the opening of its Singapore facility, which has enhanced manufacturing capacity and regional service capabilities [1][3] Company Overview - Cytek Biosciences is a leader in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Expansion Impact - The Singapore facility, which spans 8,500 square feet, has contributed to Cytek's growth by improving supply chain resilience and reducing delivery times in key markets [1][3] - The facility includes a dedicated service and training center, providing regional access to Cytek instruments and technical expertise [3] Strategic Importance - The Singapore operations are a critical component of Cytek's regional manufacturing strategy, supporting the growing demand for cell analysis solutions in the life sciences sector [2][3] - The investment in Singapore aligns with the country's goals to strengthen its MedTech ecosystem and advance life sciences research [4]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][14] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [6][24] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross margin of 53% compared to 59% in the prior year [17][18] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [20][22] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025 compared to the prior year, with a 26% growth in Q4 [8] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of reagents [10][16] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [16] Market Data and Key Metrics Changes - In the U.S., total revenue grew by 5% in Q4, driven by double-digit growth in service revenue, while EMEA grew 21% due to strong demand from academic and government customers [17] - APAC, including China, experienced a 15% growth in Q4, driven by increases in instruments, service, and reagents [17] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions by focusing on core strategic pillars: instrument, application, bioinformatics, and clinical [7] - The company plans to continue expanding its global footprint and enhancing its operational capabilities, including a new manufacturing facility in Singapore [11] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, particularly in academic and government spending, which contributed to the revenue growth in Q4 [42] - The company anticipates continued growth in 2026, with a revenue outlook of $205 million to $212 million, reflecting improved market conditions in EMEA and the U.S. [31][32] Other Important Information - The company reported a free cash flow of -$0.2 million in Q4, with total cash and marketable securities at $261.5 million as of December 31, 2025 [24][30] - The company repurchased approximately $15.1 million of its stock during 2025, reflecting a commitment to returning value to shareholders [30] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with some catch-up disbursements from the NIH [42][43] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [50] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in its sales teams and reagent sales force to drive future revenue growth [52][53]

Core Insights - Cytek Biosciences reported strong revenue growth in Q4 2025, with total revenue reaching $62.1 million, an 8% increase compared to Q4 2024, driven by robust FSP instrument sales and recurring revenue streams [3][4][8] - The company aims to focus on high-margin recurring revenue growth, instrument adoption, innovative product pipeline advancement, and sustainable growth in the cell analysis market for 2026 [3] Financial Performance - Q4 2025 total revenue was $62.1 million, marking an 8% increase from Q4 2024, the highest quarterly revenue in the company's history [4][8] - Full year 2025 total revenue was $201.5 million, a 1% increase compared to 2024, with recurring revenue growing 21% to account for 34% of total revenue [8][13] - GAAP gross profit for Q4 2025 was $32.9 million, a 2% decrease from Q4 2024, with a gross profit margin of 53% [5][8] - Operating expenses for Q4 2025 were $38.5 million, a 25.5% increase from Q4 2024, primarily due to higher general and administrative and sales and marketing expenses [6][9] - The company reported a net loss of $44.1 million in Q4 2025, compared to a net income of $9.6 million in Q4 2024, largely due to a non-cash valuation allowance against deferred tax assets [10][18] Operational Highlights - Cytek expanded its installed base to 3,664 instruments, with 630 new placements in 2025, and saw a 22% increase in unit placements of the Aurora CS system [8] - The company launched the Cytek Aurora™ Evo system and the Cytek MuseMicro cell analyzer, the latter winning the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year [8] Future Outlook - For 2026, Cytek projects revenue in the range of $205 million to $212 million, representing a growth of 2% to 5% over 2025 [21]

Core Insights - Cytek Biosciences, Inc. will participate in the TD Cowen 46 Annual Health Care Conference in Boston, MA [1] - The management is scheduled for a hybrid presentation and fireside chat on March 4 at 8:10 a.m. Pacific Time [2] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that focuses on high-resolution, high-content, and high-sensitivity cell analysis using its patented Full Spectrum Profiling™ (FSP) technology [3] - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [3] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3] Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [4] Information Distribution - Cytek utilizes its website, LinkedIn page, and X account, in addition to SEC filings and press releases, to distribute material information and comply with disclosure obligations [5]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q4 and full year 2025 on February 26, 2026, with a conference call to discuss the results and outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [2]. - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [2]. - Cytek is headquartered in Fremont, California, and has a global presence with offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [3]. Information Distribution - Cytek utilizes various channels, including its website, LinkedIn page, and X account, to distribute information about the company, products, and financial announcements, complying with Regulation FD [4].

Investor Presentation January 2026 Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek's market position and long-term market expansion opportunities; Cytek's business, product and operational goals and strategies; and Cytek's opp ...

Core Insights - Cytek Biosciences, Inc. has been recognized as one of America's Growth Leaders of 2026 by TIME in partnership with Statista, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][14]. Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver innovative tools for laboratories [7]. - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [7]. Financial Performance - The inclusion in TIME's list signifies Cytek's strong financial foundation and sustained business expansion, reflecting its ability to deliver long-term value [2][5]. - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, indicating their significant impact on global research [4]. Innovation and Technology - Cytek's mission is to make high-parameter cell analysis more accessible and cost-effective, addressing urgent challenges in health and science, such as cancer research and vaccine development [3]. - The company's FSP technology sets a new standard in flow cytometry, enhancing the precision and sensitivity of cell analysis [3][7]. Market Position - Being named to the Growth Leaders list places Cytek among an elite group of companies demonstrating resilience and a forward-looking approach in a dynamic market [5].

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences, Inc. has been awarded the title of Drug Discovery Solution of the Year for its Cytek Muse Micro cell analyzer at the 2025 BioTech Breakthrough Awards, recognizing its innovative contributions to the life sciences and biotechnology sectors [1][3][10] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Product Highlights - The Cytek Muse Micro cell analyzer enhances the original Guava Muse system, offering a compact, cost-effective, and multifunctional platform that simplifies flow cytometry while maintaining accuracy and versatility [2][4] - Applications of the Muse Micro system include cell counting, cell health and viability assessment, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis [2] Market Impact - The Muse Micro system aims to democratize access to sophisticated cell analysis, making it more accessible for smaller labs and resource-limited facilities, which traditionally faced barriers due to the complexity and cost of traditional flow cytometry systems [3][4]

Core Insights - Cytek Biosciences, Inc. is launching a two-part research support initiative to enhance accessibility to cell analysis amid reduced government funding and global economic challenges [1][2][3] Group 1: Initiative Details - The first phase involves awarding a three-laser Cytek Northern Lights™ flow cytometer, which utilizes Full Spectrum Profiling™ technology for versatile assays [2][3] - The second phase will introduce a grant program for funding eligible research projects, assessed through a merit-based process overseen by a scientific advisory board [3] Group 2: Collaboration and Impact - Cytek's initiatives are part of an ongoing collaboration with the International Society for Advancement of Cytometry (ISAC) to improve access to advanced cytometry tools globally [4] - A previous donation of a Cytek Northern Lights™ flow cytometer to a lab in Argentina exemplifies the impact of collaboration in empowering scientists in underserved communities [4] Group 3: Company Commitment - Cytek is dedicated to democratizing access to flow cytometry, ensuring that labs of all sizes and budgets can utilize advanced tools for cellular insights [5] - The company emphasizes the importance of community engagement alongside technological innovation to benefit the entire scientific community [5][7]